PR Newswire Clinical TrialsOriginal article
Eisai Presents Latest Findings Showed Etalanetug Reduced Alzheimer's Disease Tau Tangle-Specific Plasma Biomarker MTBR-tau243 at Alzheimer's Association International Conference® (AAIC®) 2026
ConferencepositiveetalanetugPositive
AI Analysis
Summary
Eisai presented data at AAIC 2026 showing etalanetug reduced the Alzheimer's disease tau biomarker MTBR-tau243, suggesting the plasma biomarker may be useful for future clinical development. The findings support eMTBR-tau243 as a practical, non-invasive method for measuring disease-specific pathological changes.
Outcome Details
etalanetug reduced tau tangle-specific plasma biomarker MTBR-tau243; eMTBR-tau243 may serve as practical, less invasive biomarker for Alzheimer's disease pathological changes
Importance:5/10
Sentiment:
0.70
Alzheimer's diseasebiomarkertau pathologyAAIC 2026plasma biomarker
Related Companies
Read the original article
Published by PR Newswire Clinical Trials on July 13, 2026 8:00 AM